By Mill Chart
Last update: Feb 16, 2024
Take a closer look at GILEAD SCIENCES INC (NASDAQ:GILD), a remarkable value stock uncovered by our stock screener. NASDAQ:GILD excels in fundamentals and maintains a very reasonable valuation. Let's break it down further.
ChartMill assigns a Valuation Rating to each stock, ranging from 0 to 10. This rating is calculated by analyzing different valuation elements, such as price to earnings and free cash flow, both in absolute terms and relative to the market and industry. In the case of NASDAQ:GILD, the assigned 7 reflects its valuation:
ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NASDAQ:GILD, the assigned 7 is a significant indicator of profitability:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:GILD has received a 5 out of 10:
Every stock receives a Growth Rating from ChartMill, ranging from 0 to 10. This rating assesses various growth aspects, including historical and projected EPS and revenue growth. NASDAQ:GILD boasts a 4 out of 10:
Every day, new Decent Value stocks can be found on ChartMill in our Decent Value screener.
Our latest full fundamental report of GILD contains the most current fundamental analsysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
GILEAD SCIENCES INC
NASDAQ:GILD (4/26/2024, 7:00:00 PM)
After market: 65.5 +0.08 (+0.12%)65.42
+0.15 (+0.23%)
Despite an arsenal of drugs, many Americans are still unaware of their infections until it’s too late. A Biden initiative languishes without Congressional approval.
Explore these three dividend stocks trading near their 52-week lows, presenting compelling opportunities for income-oriented investors.
GILD earnings call for the period ending March 31, 2024.
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gilead Sciences (NASDAQ:GILD) just reported results for the first quarter of 20...
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top S&P500 gainers and losers in today's after hours session.
Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury.
Uncovering Dividend Opportunities with GILEAD SCIENCES INC (NASDAQ:GILD).